Evidence map›Paper›PMID 26236326›Full record

ReviewFrontiers in plant science2015

MorTAL Kombat: the story of defense against TAL effectors through loss-of-susceptibility.

Mathilde Hutin, Alvaro L Pérez-Quintero, Camilo Lopez, Boris Szurek

Erratum issuedOpen access · goldAbstract readReview
In one paragraph

Review in Frontiers in plant science, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 53 papers.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed
15.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 86 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Rice SUT and SWEET Transporters.International journal of molecular sciences · 2021
    Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 1 institution in 2 countries.

Mathilde HutinUMR IPME, Institut de Recherche Pour le Développement, IRD-CIRAD-Université Montpellier 2 Montpellier, France.
Alvaro L Pérez-QuinteroUMR IPME, Institut de Recherche Pour le Développement, IRD-CIRAD-Université Montpellier 2 Montpellier, France.
Camilo LopezUMR IPME, Institut de Recherche Pour le Développement, IRD-CIRAD-Université Montpellier 2 Montpellier, France ; Biology Department, Universidad Nacional de Colombia Bogota, Colombia.
Boris SzurekUMR IPME, Institut de Recherche Pour le Développement, IRD-CIRAD-Université Montpellier 2 Montpellier, France.
Centre de Coopération Internationale en Recherche Agronomique pour le Développement · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Many plant-pathogenic xanthomonads rely on Transcription Activator-Like (TAL) effectors to colonize their host. This particular family of type III effectors functions as specific plant transcription factors via a programmable DNA-binding domain. Upon binding to the promoters of plant disease susceptibility genes in a sequence-specific manner, the expression of these host genes is induced. However, plants have evolved specific strategies to counter the action of TAL effectors and confer resistance. One mechanism is to avoid the binding of TAL effectors by mutations of their DNA binding sites, resulting in resistance by loss-of-susceptibility. This article reviews our current knowledge of the susceptibility hubs targeted by Xanthomonas TAL effectors, possible evolutionary scenarios for plants to combat the pathogen with loss-of-function alleles, and how this knowledge can be used overall to develop new pathogen-informed breeding strategies and improve crop resistance.

Indexed as

agricultural biotechnologyhubsloss-of-function allelesplant disease susceptibility S genesTAL effectorsXanthomonas

Identifiers

PMID26236326
PMCPMC4500901
OpenAlexW1567288417

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.